| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0022-3956(93)90037-3 |
| P698 | PubMed publication ID | 8295158 |
| P50 | author | Robert D. Gibbons | Q46996511 |
| P2093 | author name string | Clark DC | |
| Kupfer DJ | |||
| P433 | issue | 3 | |
| P304 | page(s) | 259-273 | |
| P577 | publication date | 1993-07-01 | |
| P1433 | published in | Journal of Psychiatric Research | Q6295810 |
| P1476 | title | Exactly what does the Hamilton Depression Rating Scale measure? | |
| P478 | volume | 27 |
| Q44189457 | A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects |
| Q48176000 | A factor analytic study in bipolar depression, and response to lamotrigine |
| Q33782206 | A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned |
| Q34941312 | A staging approach to measuring patient-centred subjective outcomes. |
| Q44119946 | Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms |
| Q48876885 | An IRT validation of the Affective Self Rating Scale |
| Q34090610 | An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. |
| Q33518761 | Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials |
| Q33960815 | Assessing full remission. |
| Q36511681 | Assessment of outcome in depression |
| Q42379485 | Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials |
| Q50803208 | Biochemical and psychiatric predictors of Li(+) response and toxicity in Li(+)-treated bipolar patients |
| Q91274876 | Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials |
| Q84447263 | Can quality of life scales tell us when patients begin to feel the benefits of antidepressants? |
| Q39296186 | Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks |
| Q34513108 | Clinical methodology and its implications for the study of therapeutic interventions for chronic fatigue syndrome: a commentary |
| Q36183614 | Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample |
| Q35634140 | Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: an open study |
| Q30882594 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data |
| Q21284737 | Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-analysis |
| Q28550946 | Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression |
| Q44849427 | Correlation between cerebral blood flow and items of the Hamilton Rating Scale for Depression in antidepressant-naive patients |
| Q88546015 | Cross-Cultural Psychometric Properties of the Hamilton Depression Rating Scale |
| Q47251368 | Cross-cultural equivalence in depression assessment: Japan-Europe-North American study |
| Q44967570 | Depressive dimensions and item response analysis of the Hamilton Depression Rating Scale–17 in eating disorders |
| Q41459287 | Depressive illness and the possibilities of somatic antidepressant treatment |
| Q38777348 | Descriptive diagnostic assessment of depression Categorical diagnosis, dimensional assessment, and instruments |
| Q44126419 | Do prefrontal midline electrodes provide unique neurophysiologic information in Major Depressive Disorder? |
| Q51912832 | Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder |
| Q50791537 | Elucidating postpartum depression through statistics |
| Q24798364 | Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish Version 4 in South America: classic psychometric and item response theory analyses |
| Q34836921 | Excellent reliability of the Hamilton Depression Rating Scale (HDRS-21) in Indonesia after training |
| Q51898251 | Face-to-face versus remote administration of the Montgomery-Asberg Depression Rating Scale using videoconference and telephone |
| Q47339222 | Factor structure of the Depression Self-Rating Scale in an Iranian adolescent sample |
| Q39861093 | Functioning and validity of a Computerized Adaptive Test to measure anxiety (A-CAT). |
| Q48456170 | Further evidence that the cutoff to define remission on the 17-item Hamilton Depression Rating Scale should be lowered |
| Q47898424 | How does the Hospital and Anxiety and Depression Scale measure anxiety and depression in healthy subjects? |
| Q37409712 | Inter-rater reliability of Hamilton depression rating scale using video- recorded interviews - Focus on rater-blinding |
| Q37154168 | Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline |
| Q54009229 | Letter to the editor: A 10-item Hamilton Depression Rating Scale to measure major depressive episode severity in outpatients |
| Q51101013 | Major depressive subtypes and treatment response |
| Q34699544 | Measuring depression: comparison and integration of three scales in the GENDEP study |
| Q34132596 | Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. |
| Q74249053 | Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale |
| Q46952206 | Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos |
| Q47773431 | Performance of the Hamilton Depression Rating Scale in depressed patients in the United Arab Emirates. |
| Q48786821 | Pharmacologic Treatments Effective in Both Generalized Anxiety Disorder and Major Depressive Disorder: Clinical and Theoretical Implications |
| Q55343118 | Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study. |
| Q44209591 | Predictive socioeconomic and clinical profiles of antidepressant response and remission |
| Q34529669 | Psychometric properties of responses by clinicians and older adults to a 6-item Hebrew version of the Hamilton Depression Rating Scale (HAM-D6). |
| Q51053719 | Psychopathological dimensions of depression: a factor study of the 17-item Hamilton depression rating scale in unipolar depressed outpatients |
| Q35019889 | Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales |
| Q51806553 | Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials |
| Q33894019 | Reliability and validity of depression assessment among persons with HIV in sub-Saharan Africa: systematic review and meta-analysis |
| Q48790319 | Reviving the SCNP Committee on clinical trials: the need to enhance its future mission |
| Q35036979 | SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial |
| Q35872076 | Scale matters: the need for a Bipolar Depression Rating Scale (BDRS). |
| Q45172283 | Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients |
| Q45928384 | Sensitivity to changes during antidepressant treatment: a comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal |
| Q36082786 | Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression |
| Q52955808 | Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices |
| Q45718834 | Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression |
| Q73035513 | The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G) |
| Q34018005 | The DSM-IV definition of severity of major depression: inter-relationship and validity |
| Q42635264 | The Inventory of Depressive Symptomatology (IDS): psychometric properties. |
| Q50560433 | The Major Depression Rating Scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials. Danish University Antidepressant Group |
| Q36257510 | The Major Depressive Disorder Hierarchy: Rasch Analysis of 6 items of the Hamilton Depression Scale Covering the Continuum of Depressive Syndrome |
| Q36296747 | The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures |
| Q35111772 | The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach |
| Q36070297 | The factor structure of lifetime depressive spectrum in patients with unipolar depression. |
| Q73497518 | The responsiveness of the Hamilton Depression Rating Scale |
| Q37666047 | Therapeutic alliance in face-to-face and telephone-administered cognitive behavioral therapy |
| Q61480103 | Toward a generalizable model of symptoms in major depressive disorder |
| Q38896055 | Toward a very brief self-report to assess the core symptoms of depression (VQIDS-SR5 ). |
| Q44624709 | Trigeminal nerve stimulation in major depressive disorder: Acute outcomes in an open pilot study |
| Q48784928 | Underestimating the severity of bipolar depression: a comparison of the Hamilton Depression Rating Scale items |
| Q34443430 | Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review |
| Q35025965 | Unique design issues in clinical trials of patients with bipolar affective disorder |
| Q34047630 | Using computerized adaptive testing to reduce the burden of mental health assessment |
| Q50919918 | Validation of the Bech‐Rafaelsen Mania Scale using latent structure analysis |
| Q30477558 | Voice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology. |
| Q52869677 | What do anxiety scales measure? |
Search more.